The Argentinean laboratory Elea and the British company Phoenix –which is part of the firm GlaxoSmithKline – have sold many of their non-core products in Argentina.
The Argentinean laboratory Elea and the British company Phoenix –which is part of the firm GlaxoSmithKline – have sold many of their non-core products in Argentina.
Elea has got rid of the antidiabetic Diaben, the antiasthmatic Lirtodac, the antibiotic Memento, the bronchodilator Sedacris, and the analgesics Mox Forte and Mox 12hs.
Phoenix, on the other hand, has sold the prostate treatment Daric, the calcium- therapeutic Decalcit, the calcium regulator Elasterin, the anxiolytic Edictum, and the antidepressant Karile.
Both laboratories sold their products to the laboratory Pharmadorf, that in Argentina is leaded by Jorge Alarco, and the total sum of the transaction was approximately u$s 5 millions, according to local analysts interviewed by Pharmabiz.
Pharmadorf was founded in Argentina in 2002, and was acquired by Sanfer in November 2008. The company had bought products from Phoenix before, and that operation was also reported by Pharmabiz. See article
